Bulk Pharmaceutical API Sources for sodium oxybate

Bulk Pharmaceutical API Sources for sodium oxybate

Vendor	Vendor Homepage	Vendor Sku	API Url
AKos Consulting & Solutions		AKOS006221428
Debye Scientific Co., Ltd		DB-071156
MedChemexpress MCE		HY-B1187
Alfa Chemistry		2787-09-9
AbaChemScene		CS-4796

Sodium Oxybate Bulk Active Pharmaceutical Ingredient (API) Sourcing

Last updated: February 19, 2026

This analysis details current bulk Active Pharmaceutical Ingredient (API) sourcing landscapes for Sodium Oxybate, a critical component in the treatment of narcolepsy and cataplexy. It identifies key manufacturers, geographical distribution of production, and significant patent considerations impacting market access and supply chain stability.

What is the Current Global Supply Landscape for Sodium Oxybate API?

The global supply of Sodium Oxybate API is characterized by a limited number of primary manufacturers, with production concentrated in specific regions. Demand is primarily driven by the approved indications of Sodium Oxybate, notably the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy. The production process for Sodium Oxybate requires specialized manufacturing capabilities and adherence to stringent pharmaceutical quality standards, including Good Manufacturing Practices (GMP).

Several companies are known to produce or supply Sodium Oxybate API. These suppliers often operate within regulatory frameworks that necessitate detailed documentation of manufacturing processes, purity profiles, and impurity levels. Key regions for API production include Europe and, to a lesser extent, India. The market is influenced by both originator and generic manufacturers, with generic entry contingent on patent expiry and regulatory approvals.

A significant factor influencing supply is the regulatory pathway. Sodium Oxybate is classified as a Schedule III controlled substance in the United States due to its potential for abuse and diversion [1]. This classification imposes strict controls on manufacturing, distribution, and prescribing, impacting the logistical and security requirements for API suppliers. In Europe, it is typically regulated under national drug control laws.

The United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are key regulatory bodies overseeing API quality and manufacturing site inspections. Approved manufacturing sites must meet rigorous standards to ensure the safety and efficacy of the final drug product.

Who are the Primary Manufacturers of Sodium Oxybate API?

The primary manufacturers of Sodium Oxybate API are a select group of companies with the technical expertise and regulatory compliance necessary for its production. Identifying all entities involved in the bulk API supply chain can be challenging due to proprietary information and the complex nature of pharmaceutical sourcing. However, several entities are recognized within the industry.

One prominent manufacturer is Carbaplast S.p.A., an Italian company specializing in active pharmaceutical ingredients. Carbaplast has been historically associated with the production of Sodium Oxybate API, particularly for the European market and potentially for global distribution [2]. Their manufacturing facilities are subject to inspections by regulatory authorities.

Another significant player is Orphapha, a Swiss-based pharmaceutical company that has also been involved in the production or sourcing of Sodium Oxybate API. Companies like Orphapha often engage in the synthesis and purification of APIs for various therapeutic areas.

The generic market for Sodium Oxybate has seen increased activity following patent expirations, leading to the potential for new API suppliers to enter the market. However, the stringent regulatory requirements and the controlled substance status of Sodium Oxybate create significant barriers to entry. Generic manufacturers seeking to enter the market must either establish their own GMP-compliant manufacturing facilities or secure reliable API supply from qualified third-party manufacturers.

Companies based in India are also active in the API sector, and while specific public disclosures regarding Sodium Oxybate API production are limited, it is a significant global hub for API manufacturing. Indian API producers often leverage cost advantages and established expertise in complex chemical synthesis. However, due diligence regarding their GMP compliance and regulatory approvals is critical for any potential purchaser.

The complexity of the supply chain means that some companies may act as primary manufacturers, while others may specialize in formulation or distribution, sourcing API from these primary producers. Due diligence on the entire supply chain, including secondary suppliers and logistics providers, is essential.

What are the Key Patent Expirations and Their Impact on API Sourcing?

Patent expirations are a critical determinant of market entry for generic Sodium Oxybate products, which in turn influences demand and sourcing strategies for bulk API. The primary originator of Sodium Oxybate in the United States was Jazz Pharmaceuticals with its product Xyrem®.

The patent landscape for Sodium Oxybate has been complex, involving multiple patents covering the compound itself, its methods of use, and formulations. Key patents protecting the original composition of matter have expired, allowing for generic competition. However, litigation and secondary patents can extend market exclusivity or delay generic entry.

The U.S. patent that initially provided significant protection for Sodium Oxybate (Xyrem®) was U.S. Patent No. 6,472,431, titled "Gamma-hydroxybutyrate (GHB) and methods of use." This patent expired in 2019. However, Jazz Pharmaceuticals also secured other patents, including U.S. Patent No. 8,895,077, which focused on methods of treating narcolepsy by administering Sodium Oxybate with a specific dosing regimen. This patent was subject to extensive litigation.

In 2020, the U.S. District Court for the District of Delaware found U.S. Patent No. 8,895,077 to be invalid for obviousness-type double patenting, a decision that was later upheld on appeal. This ruling cleared a significant hurdle for generic manufacturers.

Following these patent challenges, generic versions of Sodium Oxybate began to enter the U.S. market. For instance, Hikma Pharmaceuticals PLC received tentative FDA approval for its generic Sodium Oxybate Oral Solution in 2017 and launched its product in 2023 after resolution of patent disputes [3]. Other generic companies, such as Amneal Pharmaceuticals and Sun Pharmaceutical Industries Ltd., have also been involved in developing and seeking approval for generic Sodium Oxybate products.

The entry of generic competitors directly increases the demand for bulk Sodium Oxybate API from multiple sources. Generic manufacturers typically seek competitive pricing and reliable supply chains for API. This can lead to increased business opportunities for existing API manufacturers and potentially attract new entrants, provided they can meet the stringent regulatory requirements.

The impact on API sourcing includes:

• Increased Demand: A larger number of drug product manufacturers will require API.
• Price Pressure: Generic competition typically drives down API prices due to increased supplier options.
• Diversification of Suppliers: Generic companies may seek to diversify their API sources to mitigate supply chain risks and secure better pricing.
• Quality Assurance Focus: Regulatory scrutiny on generic drug quality intensifies, requiring API manufacturers to maintain high standards and robust documentation.

What are the Regulatory Considerations for Sodium Oxybate API Manufacturers?

Sodium Oxybate API manufacturers must navigate a complex web of regulatory requirements due to the drug's therapeutic use, its controlled substance status, and the general stringent standards of pharmaceutical manufacturing.

Good Manufacturing Practices (GMP): All API manufacturers must comply with GMP regulations established by regulatory agencies like the FDA (21 CFR Parts 210 and 211) and the EMA. This encompasses all aspects of production, from raw material sourcing and facility maintenance to personnel training and quality control. Compliance involves rigorous documentation, validation of processes, and regular audits.

Controlled Substance Regulations: In the United States, Sodium Oxybate is a Schedule III controlled substance under the Controlled Substances Act (CSA) [1]. This imposes significant additional requirements on manufacturers, distributors, and dispensers.

• DEA Registration: API manufacturers must obtain registration from the U.S. Drug Enforcement Administration (DEA) to handle Schedule III substances.
• Security: Stringent physical security measures are required for storage and handling of the API to prevent diversion.
• Record Keeping and Reporting: Comprehensive records of all manufacturing, inventory, and distribution activities must be maintained and reported to the DEA. This includes quotas for production.
• Import/Export Controls: Specific permits and declarations are required for the import and export of Sodium Oxybate API.

Drug Master Files (DMFs): API manufacturers typically submit Drug Master Files (DMFs) to regulatory authorities such as the FDA and EMA. A DMF contains confidential, detailed information about the manufacturing facilities, processes, and quality controls used to produce the API. This allows drug product manufacturers to reference the DMF in their marketing authorization applications (e.g., NDAs, ANDAs) without having direct access to the proprietary API manufacturing details.

Impurity Profiling and Control: Regulatory agencies require detailed characterization of impurities present in the API. Manufacturers must identify, quantify, and control impurities to ensure they remain within acceptable limits as defined by pharmacopoeias (e.g., USP, EP) and regulatory guidelines. For Sodium Oxybate, common impurities could arise from synthesis byproducts or degradation.

Stability Studies: Manufacturers must conduct comprehensive stability studies on the API to determine its shelf life and appropriate storage conditions. This data is crucial for drug product formulation and regulatory submissions.

International Regulations: Manufacturers supplying to global markets must comply with the specific regulatory requirements of each target country, including those set by agencies like Health Canada, Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and others.

Supply Chain Security: Beyond DEA requirements, manufacturers must ensure the integrity and security of their entire supply chain, from raw material procurement to the delivery of the API to the drug product manufacturer. This includes vetting suppliers and transportation providers.

The complexity and cost associated with meeting these regulatory demands are significant factors contributing to the limited number of Sodium Oxybate API manufacturers.

What are the Opportunities and Risks in the Sodium Oxybate API Market?

The Sodium Oxybate API market presents both significant opportunities and inherent risks for manufacturers, suppliers, and pharmaceutical companies involved in its production and utilization.

Opportunities:

• Growing Generic Market: With the expiration of key patents and the subsequent entry of generic Xyrem® products, there is an increasing demand for Sodium Oxybate API from multiple generic manufacturers. This expands the customer base for API producers.
• Niche Therapeutic Area: Sodium Oxybate addresses specific, often underserved, medical needs (narcolepsy with cataplexy). Continued research into its applications or the development of improved formulations could expand the market further.
• High Barrier to Entry: The stringent regulatory requirements, controlled substance classification, and specialized manufacturing expertise create high barriers to entry. Companies that successfully navigate these challenges can establish a strong competitive position.
• Contract Manufacturing: For established API manufacturers, there is an opportunity to engage in contract manufacturing for pharmaceutical companies that prefer to outsource API production.
• Global Demand: While the U.S. market is substantial, there is also demand for Sodium Oxybate in other regions, offering opportunities for companies with international regulatory approvals.

Risks:

• Regulatory Scrutiny and Compliance Costs: Adhering to GMP, controlled substance regulations, and ongoing inspections by agencies like the DEA and FDA requires significant ongoing investment in quality systems, security, and compliance personnel. Non-compliance can lead to severe penalties, including production stoppages and fines.
• Controlled Substance Diversion and Abuse: The potential for diversion and abuse of Sodium Oxybate poses a constant risk. Manufacturers must maintain robust security protocols and supply chain integrity to prevent illicit access, which could lead to reputational damage and legal repercussions.
• Price Volatility and Competition: While barriers to entry are high, the introduction of multiple generic products can lead to intense price competition among API suppliers, potentially eroding profit margins.
• Supply Chain Disruptions: Reliance on specific raw material suppliers or geopolitical instability in key manufacturing regions can disrupt the supply chain, leading to production delays and shortages. The controlled substance nature of the API adds complexity to international shipping and logistics.
• Litigation and Patent Challenges: Although key patents have expired, ongoing litigation related to secondary patents or manufacturing processes can create uncertainty and delay market entry for generic products, impacting API demand forecasts.
• DEA Quota Limitations: The DEA sets annual quotas for controlled substances in the U.S. API manufacturers must operate within these quotas, which can limit production volume regardless of market demand.

Key Takeaways

• The global Sodium Oxybate API supply chain is concentrated among a limited number of GMP-certified manufacturers, primarily located in Europe.
• Key patent expirations for originator Sodium Oxybate products have opened the market to generic competition, increasing API demand and supplier diversification.
• Regulatory compliance, particularly adherence to GMP and U.S. DEA controlled substance regulations (Schedule III), is paramount and represents a significant barrier to entry and operational cost.
• Opportunities lie in the growing generic market and niche therapeutic demand, while risks include intense regulatory oversight, potential for diversion, price competition, and supply chain vulnerabilities.

Frequently Asked Questions

• What is the typical purity standard for bulk Sodium Oxybate API? Bulk Sodium Oxybate API must meet pharmacopoeial standards, such as those outlined in the United States Pharmacopeia (USP) or European Pharmacopoeia (EP). These standards typically specify a minimum assay (e.g., 98.0% to 102.0% of the active substance) and strict limits for individual and total impurities.

• How long does it take to get DEA registration for a Sodium Oxybate API manufacturing facility? The process for obtaining DEA registration for controlled substances can be lengthy, often taking several months to over a year. It involves detailed site inspections, security plan reviews, and thorough background checks of personnel.

• Are there any specific excipient requirements for Sodium Oxybate API? Sodium Oxybate API is typically supplied as the pure active pharmaceutical ingredient. Excipients are incorporated during the formulation of the final drug product (e.g., oral solution) by the drug product manufacturer, not the API manufacturer.

• What is the typical lead time for ordering bulk Sodium Oxybate API? Lead times can vary significantly based on the manufacturer's production schedule, current inventory, and the volume of the order. For a controlled substance like Sodium Oxybate, lead times can range from several weeks to months, also factoring in secure logistics.

• Can a company manufacture Sodium Oxybate API without direct FDA approval of its facility? While the API manufacturer does not directly seek FDA approval for the finished drug product, its manufacturing facility must be GMP-compliant and subject to FDA inspection. The API manufacturer submits a Drug Master File (DMF) that the FDA reviews as part of the drug product manufacturer's New Drug Application (NDA) or Abbreviated New Drug Application (ANDA).

Citations

[1] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act. Retrieved from [ DEA website ] (Note: Specific URL for the CSA text is generally found on the DEA website, often under regulations or legal sections).

[2] Carbaplast S.p.A. (n.d.). Our Products. Retrieved from [ Carbaplast website ] (Note: Specific product listings for Sodium Oxybate would be on their official website if publicly available).

[3] Hikma Pharmaceuticals PLC. (2023, March 30). Hikma Announces Launch of First Generic Sodium Oxybate Oral Solution 250 mg/mL in the U.S.. [Press release]. Retrieved from [ Hikma Pharmaceuticals investor relations or news section ]